Alerion Biomedical has launched Fenestra, the first contrast enhancement product line for use in CT imaging of animals, according to the San Diego company. A single dose of the new product provides prolonged contrast enhancement of the entire
Alerion Biomedical has launched Fenestra, the first contrast enhancement product line for use in CT imaging of animals, according to the San Diego company. A single dose of the new product provides prolonged contrast enhancement of the entire hepatobiliary system, as well as functional imaging information about the liver and biliary tract.
Fenestra, the first in a planned family of products, is based on iodinated triglycerides contained in the lipophilic cores of oil-in-water lipid emulsions. These emulsions are similar to naturally occurring chylomicron remnants that carry lipids in the body. Depending on the properties engineered into the emulsion formulations, the agents provide long-lasting visualization of the hepatobiliary or vascular systems, a feature useful when imaging animals with microCT scanners. Because both uptake and elimination of the agents correlate with the metabolic status of the liver, Fenestra also provides the opportunity to evaluate hepatic function as the agent is metabolized and processed through the hepatobiliary pathway, according to the company.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.